Article Figures & Data
Tables
- Table 1.
HPV genotypes detected by line blot assay, linear array, and either line blot assay or linear array, for all and single HPV genotypes in cervical specimens from women diagnosed with CIN3
Line blot assay (n = 596) Linear array (n = 588) Line blot assay or linear array All (n = 608) Single (n = 128) % % % % Any HPV 96.0 98.1 98.9 100 Any carcinogenic HPV 92.1 94.4 95.4 89.8 Multiple HPV genotypes 64.7 77.2 77.8 Multiple carcinogenic HPV genotypes 51.3 61.3 60.0 HPV6 2.0 4.3 4.4 1.6 HPV11 1.0 1.7 1.6 0.0 HPV16 56.5 58.8 59.9 47.7 HPV18 11.2 12.4 13.2 7.0 HPV26 1.0 1.7 1.8 0.8 HPV31 14.8 17.0 18.1 10.9 HPV33 7.7 8.8 10.0 3.9 HPV35 9.2 8.8 9.4 4.7 HPV39 7.7 10.2 10.5 0.8 HPV40 1.5 1.9 2.1 0.0 HPV42 3.0 5.4 5.6 0.8 HPV45 6.7 8.3 8.4 2.3 HPV51 10.1 13.4 14.0 0.8 HPV52* 14.8 23.5† 14.8 5.5 HPV53 7.1 11.1 11.2 0.0 HPV54 6.7 9.7 10.0 0.0 HPV55 3.9 5.4 5.4 0.8 HPV56 5.0 7.0 7.2 0.8 HPV57 0.2 n/a 0.2 0.0 HPV58 7.9 9.7 9.9 5.5 HPV59 6.0 8.3 8.1 0.0 HPV61‡ 4.5 7.1 6.9 0.0 HPV62‡ 5.2 9.2 9.1 0.8 HPV64‡ 0.5 0.0 0.3 0.0 HPV66 3.9 6.1 6.3 2.3 HPV67‡ 2.9 2.4 3.0 1.6 HPV68 3.5 4.6 4.6 0.0 HPV69‡ 0.9 1.0 1.0 0.0 HPV70‡ 4.8 4.3 4.9 0.0 HPV71‡ 1.4 0.7 1.2 0.0 HPV72‡ 2.0 2.2 2.5 0.0 HPV73 2.5 3.2 3.3 0.0 HPV81‡ 2.5 4.1 4.0 0.8 HPV82 3.5 3.7 3.6 0.8 HPV82v‡ 0.0 0.5 0.5 0.0 HPV83 4.7 6.0 6.3 0.0 HPV84 3.4 8.0 8.2 0.0 HPV89‡ 4.3 6.1 6.4 0.0 ↵*HPV52 for line blot assay or linear array was based only on the line blot assay result because of the tendency of linear array to overestimate the presence of HPV52.
↵†Inferred based on testing positive for a pool of probes.
↵‡These HPV genotypes were not detected in all enrollment specimens tested by line blot assay.
- Table 2.
Characteristics of CIN3 by hierarchically defined HPV risk group: HPV16 > other carcinogenic HPV genotypes (Carc. excl. HPV16) > noncarcinogenic HPV > PCR negative
Characteristics at diagnosis n (%) HPV16 Carc. (excl. HPV16) Noncarcinogenic PCR negative P n = 364 n = 216 n = 21 n = 7 Median age (y) 608 (100) 23.5 25 24 40 0.0003 n (%) Row % Row % Row % Row % Second diagnosis <CIN2 42 (7) 36 48 10 7 <0.0005 CIN2 236 (39) 53 42 4 1 CIN3 330 (54) 68 29 2 0 Smoking status Never 247 (41) 55 41 3 2 0.005 Former 80 (13) 54 39 4 4 Current 281 (46) 66 30 4 0 Oral contraceptive use Never 156 (26) 56 40 3 1 0.04 Former 127 (21) 58 34 6 0 Current 273 (45) 66 32 2 0 Missing 52 (9) 44 46 6 0 Parity Never pregnant 162 (27) 67 29 4 0 0.03 0 births 76 (13) 66 33 1 0 1 birth 159 (26) 60 37 3 1 ≥2 births 211 (35) 52 40 5 3 Worst cytologic interpretation Negative 45 (7) 40 42 11 7 <0.0005 ASCUS 70 (12) 54 36 6 4 LSIL 107 (18) 63 35 2 1 HSIL/ASC-H 385 (63) 63 35 3 0 Study arm Immediate colposcopy 227 (37) 57 35 6 2 0.1 HPV triage 163 (27) 60 38 2 1 Conservative management 218 (36) 63 34 2 1 Abbreviations: HSIL, high-grade squamous intraepithelial lesion; ASC-H, atypical squamous cells, cannot rule out HSIL.
- Table 3.
Logistic regression model for detecting HPV16 versus other carcinogenic HPV genotypes in cervical specimens from women diagnosed with CIN3
Characteristics at diagnosis n (%) OR (95% CI) P Age (per year) 580 (100) 0.97 (0.94-1.0) 0.04 Second diagnosis <CIN2 (ref.) 35 (6) 1.0 (—) CIN2 224 (39) 1.8 (0.85-3.8) 0.1 CIN3 321 (55) 3.1 (1.5-6.4) 0.003 Parity Never pregnant (ref.) 156 (27) 1.0 (—) 0 births 75 (13) 0.95 (0.52-1.7) 0.9 1 birth 154 (27) 0.69 (0.43-1.1) 0.1 ≥2 births 195 (34) 0.57 (0.35-0.93) 0.03 Smoking status Never (ref.) 236 (41) 1.0 (—) Former 74 (13) 1.0 (0.59-1.8) 0.9 Current 270 (47) 1.7 (1.2-2.5) 0.005 NOTE: Odds ratios are mutually adjusted for all variables in the table.
Volume 19, Issue 7
